Quickly rising SARS-CoV-2 B.1.1.7 sub-lineage in the USA of America with spike protein D178H and membrane protein V70L mutations

 

Summary The SARS-CoV-2 B.1.1.7 lineage is extremely infectious and as of April 2021 accounted for 92% of COVID-19 circumstances in Europe and 59% of COVID-19 circumstances within the U.S. It’s outlined by the N501Y mutation within the receptor binding area (RBD) of the Spike (S) protein, and some different mutations. These embrace two mutations within the N terminal area (NTD) of the S protein, HV69-70del and Y144del (often known as Y145del because of the presence of tyrosine at each positions). We lately recognized a number of rising SARS-CoV-2 variants of considerations, characterised by Membrane (M) protein mutations, together with I82T and V70L. We now determine a sub-lineage of B.1.1.7 that emerged by means of sequential acquisitions of M:V70L in November 2020 adopted by a novel S:D178H mutation first noticed in early February 2021.

 

The proportion of B.1.1.7 isolates within the U.S. that belong to this sub-lineage elevated from 0.15% in February 2021 to 1.8% in April 2021. So far this sub-lineage seems to be U.S.-specific with reported circumstances in 31 states, together with Hawaii. As of April 2021 it constituted 36.8% of all B.1.1.7 isolates in Washington. Phylogenetic evaluation and transmission inference with Nextstrain suggests this sub-lineage possible originated in both California or Washington. Structural evaluation revealed that the S:D178H mutation is within the NTD of the S protein and shut to 2 different signature mutations of B.1.1.7, HV69-70del and Y144del. It’s floor uncovered and will alter NTD tertiary configuration or accessibility, and thus has the potential to have an effect on neutralization by NTD directed antibodies.

 

Speedy three-dimensional form willpower of globular proteins by mobility capillary electrophoresis and native mass spectrometry

Established high-throughput proteomics strategies present restricted data on the stereostructures of proteins. Conventional applied sciences for protein construction willpower sometimes require laborious steps and can’t be carried out in a high-throughput style. Right here, we report a brand new medium throughput methodology by combining mobility capillary electrophoresis (MCE) and native mass spectrometry (MS) for the three-dimensional (3D) form willpower of globular proteins within the liquid section, which offers each the geometric construction and molecular mass data of proteins.

A principle was established to correlate the ion hydrodynamic radius and cost state distribution within the native mass spectrum with protein geometrical parameters, by means of which a low-resolution construction (form) of the protein might be decided. Our take a look at information of 11 completely different globular proteins confirmed that this method permits us to find out the shapes of particular person proteins, protein complexes and proteins in a mix, and to watch protein conformational modifications. Moreover offering complementary protein construction data and having combination evaluation functionality, this MCE and native MS primarily based methodology is quick in velocity and low in pattern consumption, making it probably relevant in top-down proteomics and structural biology for intact globular protein or protein advanced evaluation.

 

Quick floor immobilization of native proteins by means of catalyst-free amino-yne click on bioconjugation

Floor immobilization offers a helpful platform for biosensing, drug screening, tissue engineering and different chemical and organic functions. Nonetheless, a number of the used reactions are inefficient and/or sophisticated, limiting their functions in immobilization. Herein, we use a spontaneous and catalyst-free amino-yne click on bioconjugation to generate activated ethynyl group functionalized surfaces for quick immobilization of native proteins and cells.

Biomolecules, resembling bovine serum albumin (BSA), human IgG and a peptide of C(RGDfK), might be covalently immobilized on the surfaces in as brief as 30 min. Notably, the bioactivity of the anchored biomolecules stays intact, which is verified by effectively capturing goal antibodies and cells from the majority options. This technique represents an alternate for extremely environment friendly floor biofunctionalization.

 

On the binding response of loratadine with human serum acute section protein alpha 1-acid glycoprotein

Loratadine is a crucial anti-allergic drug. It’s a second era antihistamine drug used to deal with allergic rhinitis, hay fever and urticaria. Human serum alpha 1-acid glycoprotein (AG) is a crucial acute section protein and its serum focus is discovered to extend in irritation and acute response.The binding interplay between loratadine and AG is studied utilizing spectroscopy and molecular docking strategies. The outcomes obtained from fluorescence quenching experiments demonstrated that the fluorescence depth of AG is quenched by loratadine. Loratadine was discovered to bind AG with the binding fixed of ≈10⁴ at 298 Ok.

The Gibb’s free power change was discovered to be destructive for the interplay of loratadine with AG indicating the binding course of is spontaneous. Binding of loratadine with AG induced ordered constructions within the protein. Hydrogen bonding and hydrophobic interactions had been the principle bonding forces between AG-loratadine as revealed by molecular docking outcomes. This research suggests the significance of binding of anti-allergic drug to AG spatially within the ailments the place the plasma focus of AG will increase many folds and interplay with this protein turns into important. This research will assist in design of drug dosage and adjustment accordingly to realize optimum therapy consequence. Communicated by Ramaswamy H. Sarma.

Focused Protein Degradation by means of Quick Optogenetic Activation and Its Utility to the Management of Cell Signaling

Improvement of methodologies for optically triggered protein degradation permits the research of dynamic protein capabilities, such as these concerned in cell signaling, which are troublesome to be probed with conventional genetic strategies. Right here, we describe the design and implementation of a novel light-controlled peptide degron conferring N-end pathway degradation to its protein goal. The degron includes a photocaged N-terminal amino acid and a lysine-rich, 13-residue linker. By caging the N-terminal residue, we had been in a position to optically management N-degron recognition by an E3 ligase, consequently controlling ubiquitination and proteasomal degradation of the goal protein.

We reveal broad applicability by making use of this method to a various set of goal proteins, together with EGFP, firefly luciferase, the kinase MEK1, and the phosphatase DUSP6 (often known as MKP3). The caged degron can be utilized with minimal protein engineering and offers nearly full, light-triggered protein degradation on a second to minute time scale.

 

 

Anti-Total Goat Milk Proteins
4042-PA	Cygnus Technologies	1 ml	EUR 585.6
Description: Anti-Total Goat Milk Proteins by Cygnus Technologies is available in Europe via Gentaur.

Goat Milk Proteins Antigen Concentrate
F243H	Cygnus Technologies	100 ul	EUR 493.2
Description: Goat Milk Proteins Antigen Concentrate by Cygnus Technologies is available in Europe via Gentaur.

Goat Milk Proteins Control Antigen
F247	Cygnus Technologies	50 ul	EUR 308.4
Description: Goat Milk Proteins Control Antigen by Cygnus Technologies is available in Europe via Gentaur.

anti- Kv1.4-Specific antibody
FNab04664	FN Test	100µg	EUR 606.3
Description: Antibody raised against Kv1.4-Specific

Placenta Specific Protein 8 (PLAC8) Antibody
20-abx313859	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 8 (PLAC8) Antibody
abx236511-100ug	Abbexa	100 ug	EUR 577.2

Placenta Specific Protein 9 (PLAC9) Antibody
20-abx102925	Abbexa	EUR 543.60 EUR 159.60 EUR 1579.20 EUR 744.00 EUR 410.40	100 ug 10 ug 1 mg 200 ug 50 ug

Placenta Specific Protein 9 (PLAC9) Antibody
20-abx132127	Abbexa	EUR 427.20 EUR 1111.20 EUR 560.40 EUR 184.80 EUR 326.40	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 9 (PLAC9) Antibody
20-abx307413	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

anti- TDRKH specific antibody
FNab08580	FN Test	100µg	EUR 658.5
Description: Antibody raised against TDRKH specific

anti- TUBB3 specific antibody
FNab09890	FN Test	100µg	EUR 658.5
Description: Antibody raised against TUBB3 specific

anti- REDD1 specific antibody
FNab07228	FN Test	100µg	EUR 658.5
Description: Antibody raised against REDD1 specific

Lymphocyte Specific Protein 1 (LSP1) Antibody
abx234879-100ug	Abbexa	100 ug	EUR 661.2

Lymphocyte Specific Protein 1 (LSP1) Antibody
abx146154-100ug	Abbexa	100 ug	EUR 469.2

Lymphocyte Specific Protein 1 (LSP1) Antibody
abx331029-100ul	Abbexa	100 ul	EUR 510

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx113549	Abbexa	EUR 878.40 EUR 477.60	150 ul 50 ul

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx014564	Abbexa	EUR 376.80 EUR 117.60 EUR 477.60 EUR 594.00	100 ug 10 ug 200 ug 300 µg

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx131687	Abbexa	EUR 543.60 EUR 159.60 EUR 1562.40 EUR 744.00 EUR 410.40	100 ug 10 ug 1 mg 200 ug 50 ug

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx131688	Abbexa	EUR 526.80 EUR 159.60 EUR 1479.60 EUR 710.40 EUR 393.60	100 ug 10 ug 1 mg 200 ug 50 ug

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx324055	Abbexa	EUR 376.80 EUR 292.80	100 ug 50 ug

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx320072	Abbexa	EUR 360.00 EUR 292.80	100 ul 50 ul

Lymphocyte Specific Protein 1 (LSP1) Antibody
abx431359-200ul	Abbexa	200 ul	EUR 460.8

Lymphocyte Specific Protein 1 (LSP1) Antibody
abx432939-200ul	Abbexa	200 ul	EUR 460.8

Lymphocyte Specific Protein 1 (LSP1) Antibody
20-abx004294	Abbexa	EUR 493.20 EUR 710.40 EUR 218.40 EUR 376.80	100 ul 200 ul 20 ul 50 ul

Lymphocyte Specific Protein 1 Antibody / LSP1
F54824-0.08ML	NSJ Bioreagents	0.08 ml	EUR 140.25
Description: LSP1 / Lymphocyte Specific Protein 1 is an intracellular F-actin binding protein. The protein is expressed in lymphocytes, neutrophils, macrophages, and endothelium and may regulate neutrophil motility, adhesion to fibrinogen matrix proteins, and transendothelial migration. Alternative splicing results in multiple transcript variants encoding different isoforms.

Lymphocyte Specific Protein 1 Antibody / LSP1
F54824-0.4ML	NSJ Bioreagents	0.4 ml	EUR 322.15
Description: LSP1 / Lymphocyte Specific Protein 1 is an intracellular F-actin binding protein. The protein is expressed in lymphocytes, neutrophils, macrophages, and endothelium and may regulate neutrophil motility, adhesion to fibrinogen matrix proteins, and transendothelial migration. Alternative splicing results in multiple transcript variants encoding different isoforms.

LSP1 Antibody / Lymphocyte Specific Protein 1
V7928-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: LSP1 is a hematopoietic-expressed gene that encodes an F-actin-binding, leukocyte-specific (including B and T lymphocytes, granulocytes and macrophages), phosphoprotein. However, mRNA splice variants that do not encode the lympho-specific protein are expressed from this gene in nonlymphoid cell lines as well (myocytes, stromal cells and fibroblasts), suggesting pp52 has a divergent role in signal transduction. The pp52 (LSP1) locus maps to human chromosome 11p15.5, which is implicated in tumor-related chromosomal translocations found in chronic lymphocytic leukemia. The pp52 promoter contains key elements that control transcriptional activity including an initiator specifying the unique 5' terminus of pp52 mRNA, tandem pairs of Ets and SP1 motifs, and a single C/EBP motif. LSP1 binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis.

LSP1 Antibody / Lymphocyte Specific Protein 1
V7928-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: LSP1 is a hematopoietic-expressed gene that encodes an F-actin-binding, leukocyte-specific (including B and T lymphocytes, granulocytes and macrophages), phosphoprotein. However, mRNA splice variants that do not encode the lympho-specific protein are expressed from this gene in nonlymphoid cell lines as well (myocytes, stromal cells and fibroblasts), suggesting pp52 has a divergent role in signal transduction. The pp52 (LSP1) locus maps to human chromosome 11p15.5, which is implicated in tumor-related chromosomal translocations found in chronic lymphocytic leukemia. The pp52 promoter contains key elements that control transcriptional activity including an initiator specifying the unique 5' terminus of pp52 mRNA, tandem pairs of Ets and SP1 motifs, and a single C/EBP motif. LSP1 binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis.

LSP1 Antibody / Lymphocyte Specific Protein 1
V7928SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: LSP1 is a hematopoietic-expressed gene that encodes an F-actin-binding, leukocyte-specific (including B and T lymphocytes, granulocytes and macrophages), phosphoprotein. However, mRNA splice variants that do not encode the lympho-specific protein are expressed from this gene in nonlymphoid cell lines as well (myocytes, stromal cells and fibroblasts), suggesting pp52 has a divergent role in signal transduction. The pp52 (LSP1) locus maps to human chromosome 11p15.5, which is implicated in tumor-related chromosomal translocations found in chronic lymphocytic leukemia. The pp52 promoter contains key elements that control transcriptional activity including an initiator specifying the unique 5' terminus of pp52 mRNA, tandem pairs of Ets and SP1 motifs, and a single C/EBP motif. LSP1 binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis.

LSP1 Antibody / Lymphocyte Specific Protein 1
V7929-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: LSP1 is a hematopoietic-expressed gene that encodes an F-actin-binding, leukocyte-specific (including B and T lymphocytes, granulocytes and macrophages), phosphoprotein. However, mRNA splice variants that do not encode the lympho-specific protein are expressed from this gene in nonlymphoid cell lines as well (myocytes, stromal cells and fibroblasts), suggesting pp52 has a divergent role in signal transduction. The pp52 (LSP1) locus maps to human chromosome 11p15.5, which is implicated in tumor-related chromosomal translocations found in chronic lymphocytic leukemia. The pp52 promoter contains key elements that control transcriptional activity including an initiator specifying the unique 5' terminus of pp52 mRNA, tandem pairs of Ets and SP1 motifs, and a single C/EBP motif. LSP1 binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis.

LSP1 Antibody / Lymphocyte Specific Protein 1
V7929-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: LSP1 is a hematopoietic-expressed gene that encodes an F-actin-binding, leukocyte-specific (including B and T lymphocytes, granulocytes and macrophages), phosphoprotein. However, mRNA splice variants that do not encode the lympho-specific protein are expressed from this gene in nonlymphoid cell lines as well (myocytes, stromal cells and fibroblasts), suggesting pp52 has a divergent role in signal transduction. The pp52 (LSP1) locus maps to human chromosome 11p15.5, which is implicated in tumor-related chromosomal translocations found in chronic lymphocytic leukemia. The pp52 promoter contains key elements that control transcriptional activity including an initiator specifying the unique 5' terminus of pp52 mRNA, tandem pairs of Ets and SP1 motifs, and a single C/EBP motif. LSP1 binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis.

LSP1 Antibody / Lymphocyte Specific Protein 1
V7929SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: LSP1 is a hematopoietic-expressed gene that encodes an F-actin-binding, leukocyte-specific (including B and T lymphocytes, granulocytes and macrophages), phosphoprotein. However, mRNA splice variants that do not encode the lympho-specific protein are expressed from this gene in nonlymphoid cell lines as well (myocytes, stromal cells and fibroblasts), suggesting pp52 has a divergent role in signal transduction. The pp52 (LSP1) locus maps to human chromosome 11p15.5, which is implicated in tumor-related chromosomal translocations found in chronic lymphocytic leukemia. The pp52 promoter contains key elements that control transcriptional activity including an initiator specifying the unique 5' terminus of pp52 mRNA, tandem pairs of Ets and SP1 motifs, and a single C/EBP motif. LSP1 binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis.

Anti-Kv1.4-Specific antibody
PAab04664	Lifescience Market	100 ug	EUR 426

Human tumor specific protein 70 (SP70) Antibody
P1058-6ml	SAB	6ml	EUR 381.6

Anti-REDD1 specific antibody
PAab07228	Lifescience Market	100 ug	EUR 463.2

Anti-TDRKH specific antibody
PAab08580	Lifescience Market	100 ug	EUR 463.2

TDRKH Specific (TDRKH specific) Antibody
abx238580-100ug	Abbexa	100 ug	EUR 610.8

REDD1 Specific (REDD1 specific) Antibody
abx237228-100ug	Abbexa	100 ug	EUR 610.8

Placenta Specific Protein 8 (PLAC8) Antibody (HRP)
20-abx313860	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 7 (GAS7) Antibody
20-abx318799	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 1 (GAS1) Antibody
abx233349-100ug	Abbexa	100 ug	EUR 661.2

Growth Arrest Specific Protein 2 (GAS2) Antibody
abx233350-100ug	Abbexa	100 ug	EUR 610.8

Growth Arrest Specific Protein 6 (GAS6) Antibody
abx233352-100ug	Abbexa	100 ug	EUR 661.2

Growth Arrest Specific Protein 7 (GAS7) Antibody
abx233353-100ug	Abbexa	100 ug	EUR 577.2

Growth Arrest Specific Protein 8 (GAS8) Antibody
abx233354-100ug	Abbexa	100 ug	EUR 610.8

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx225183	Abbexa	EUR 444.00 EUR 727.20 EUR 376.80	100 ul 200 ul 50 ul

Growth Arrest Specific Protein 8 (GAS8) Antibody
20-abx241650	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 7 (GAS7) Antibody
20-abx242118	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 7 (GAS7) Antibody
20-abx242119	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx103339	Abbexa	EUR 477.60 EUR 159.60 EUR 1312.80 EUR 644.40 EUR 376.80	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx103340	Abbexa	EUR 510.00 EUR 159.60 EUR 1429.20 EUR 693.60 EUR 393.60	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx103341	Abbexa	EUR 477.60 EUR 159.60 EUR 1328.40 EUR 644.40 EUR 376.80	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx103342	Abbexa	EUR 493.20 EUR 159.60 EUR 1362.00 EUR 661.20 EUR 376.80	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx172674	Abbexa	EUR 944.40 EUR 493.20	1 mg 200 ug

Growth Arrest Specific Protein 8 (GAS8) Antibody
20-abx213853	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 2 (GAS2) Antibody
abx215555-100ug	Abbexa	100 ug	EUR 526.8

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx211569	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx211570	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 1 (GAS1) Antibody
20-abx212066	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx121904	Abbexa	EUR 360.00 EUR 526.80 EUR 226.80	100 ul 200 ul 30 ul

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx119561	Abbexa	EUR 376.80 EUR 117.60 EUR 477.60 EUR 594.00	100 ug 10 ug 200 ug 300 µg

Growth Arrest Specific Protein 7 (GAS7) Antibody
abx146092-100ug	Abbexa	100 ug	EUR 469.2

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx324658	Abbexa	EUR 376.80 EUR 292.80	100 ug 50 ug

Growth Arrest Specific Protein 1 (GAS1) Antibody
20-abx325561	Abbexa	EUR 376.80 EUR 292.80	100 ug 50 ug

Growth Arrest Specific Protein 1 (GAS1) Antibody
abx330964-100ul	Abbexa	100 ul	EUR 510

Growth Arrest Specific Protein 8 (GAS8) Antibody
20-abx326572	Abbexa	EUR 376.80 EUR 292.80	100 ug 50 ug

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx112854	Abbexa	EUR 878.40 EUR 477.60	150 ul 50 ul

Growth Arrest Specific Protein 7 (GAS7) Antibody
20-abx112855	Abbexa	EUR 878.40 EUR 477.60	150 ul 50 ul

Growth Arrest Specific Protein 8 (GAS8) Antibody
20-abx112856	Abbexa	EUR 878.40 EUR 477.60	150 ul 50 ul

Growth Arrest Specific Protein 2 (GAS2) Antibody
abx030639-400ul	Abbexa	400 ul	EUR 627.6

Growth Arrest Specific Protein 2 (GAS2) Antibody
abx030639-80l	Abbexa	80 µl	EUR 343.2

Growth Arrest Specific Protein 7 (GAS7) Antibody
abx032914-400ul	Abbexa	400 ul	EUR 627.6

Growth Arrest Specific Protein 7 (GAS7) Antibody
abx032914-80l	Abbexa	80 µl	EUR 343.2

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx129509	Abbexa	EUR 493.20 EUR 159.60 EUR 1362.00 EUR 661.20 EUR 376.80	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 7 (GAS7) Antibody
20-abx125870	Abbexa	EUR 493.20 EUR 710.40 EUR 376.80	100 ul 200 ul 50 ul

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx124278	Abbexa	EUR 493.20 EUR 710.40 EUR 218.40 EUR 376.80	100 ul 200 ul 20 ul 50 ul

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx130151	Abbexa	EUR 510.00 EUR 159.60 EUR 1412.40 EUR 693.60 EUR 393.60	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx130152	Abbexa	EUR 510.00 EUR 159.60 EUR 1412.40 EUR 693.60 EUR 393.60	100 ug 10 ug 1 mg 200 ug 50 ug

Growth Arrest Specific Protein 1 (GAS1) Antibody
20-abx338466	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx338601	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx339125	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 6 (GAS6) Antibody
20-abx339414	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 1 (GAS1) Antibody
20-abx339426	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Growth Arrest Specific Protein 7 (GAS7) Antibody
20-abx006749	Abbexa	EUR 493.20 EUR 710.40	100 ul 200 ul

Growth Arrest Specific Protein 8 (GAS8) Antibody
20-abx007512	Abbexa	EUR 360.00 EUR 526.80 EUR 226.80	100 ul 200 ul 30 ul

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx001082	Abbexa	EUR 493.20 EUR 710.40 EUR 218.40 EUR 376.80	100 ul 200 ul 20 ul 50 ul

Growth Arrest Specific Protein 1 (GAS1) Antibody
20-abx014505	Abbexa	EUR 376.80 EUR 117.60 EUR 477.60 EUR 594.00	100 ug 10 ug 200 ug 300 µg

Growth Arrest Specific Protein 2 (GAS2) Antibody
20-abx303935	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 9 (PLAC9) Antibody (HRP)
20-abx307414	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 8 (PLAC8) Antibody (FITC)
20-abx313861	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 9 (PLAC9) Antibody (FITC)
20-abx307415	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 8 (PLAC8) Antibody (Biotin)
20-abx313862	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Placenta Specific Protein 9 (PLAC9) Antibody (Biotin)
20-abx272460	Abbexa	EUR 577.20 EUR 292.80 EUR 1713.60 EUR 811.20 EUR 427.20	100 ug 10 ug 1 mg 200 ug 50 ug

Placenta Specific Protein 9 (PLAC9) Antibody (Biotin)
20-abx307416	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 7 (GAS7) Antibody (HRP)
20-abx316890	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 1 (GAS1) Antibody (HRP)
20-abx335868	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody (HRP)
20-abx335871	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 2 (GAS2) Antibody (HRP)
20-abx303936	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Goat Anti-Human IgG F(ab')2 fragment specific (adsorbed with bovine, horse, mouse serum proteins)
10115-UL	Alpha Diagnostics	0.5 mg	EUR 270

Growth Arrest Specific Protein 7 (GAS7) Antibody (FITC)
20-abx316891	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 1 (GAS1) Antibody (FITC)
20-abx335869	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 6 (GAS6) Antibody (FITC)
20-abx335872	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Growth Arrest Specific Protein 2 (GAS2) Antibody (FITC)
20-abx303937	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

anti- SCN9A/Nav1.7-Specific antibody
FNab07646	FN Test	100µg	EUR 702
Description: Antibody raised against SCN9A/Nav1.7-Specific

anti- Claudin 4-specific antibody
FNab01739	FN Test	100µg	EUR 606.3
Description: Antibody raised against Claudin 4-specific